|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-3-9
|
|
pubmed:abstractText |
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial arrhythmic syndrome caused by mutations in genes encoding the calcium-regulation proteins cardiac ryanodine receptor (RyR2) or calsequestrin-2 (CASQ2). Mechanistic studies indicate that CPVT is mediated by diastolic Ca(2+) overload and increased Ca(2+) leak through the RyR2 channel, implying that treatment targeting these defects might be efficacious in CPVT.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Arrhythmia Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Calsequestrin,
http://linkedlifedata.com/resource/pubmed/chemical/Diltiazem,
http://linkedlifedata.com/resource/pubmed/chemical/Magnesium,
http://linkedlifedata.com/resource/pubmed/chemical/Propranolol,
http://linkedlifedata.com/resource/pubmed/chemical/Ryanodine Receptor Calcium Release...,
http://linkedlifedata.com/resource/pubmed/chemical/Verapamil,
http://linkedlifedata.com/resource/pubmed/chemical/casq2 protein, mouse
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1540-8167
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2010 Wiley Periodicals, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
316-24
|
|
pubmed:meshHeading |
pubmed-meshheading:20807279-Adrenergic beta-Antagonists,
pubmed-meshheading:20807279-Animals,
pubmed-meshheading:20807279-Anti-Arrhythmia Agents,
pubmed-meshheading:20807279-Calcium Channel Blockers,
pubmed-meshheading:20807279-Calcium Signaling,
pubmed-meshheading:20807279-Calsequestrin,
pubmed-meshheading:20807279-Diltiazem,
pubmed-meshheading:20807279-Disease Models, Animal,
pubmed-meshheading:20807279-Electrocardiography,
pubmed-meshheading:20807279-Gene Knock-In Techniques,
pubmed-meshheading:20807279-Magnesium,
pubmed-meshheading:20807279-Mice,
pubmed-meshheading:20807279-Mice, Knockout,
pubmed-meshheading:20807279-Mutation,
pubmed-meshheading:20807279-Myocytes, Cardiac,
pubmed-meshheading:20807279-Propranolol,
pubmed-meshheading:20807279-Ryanodine Receptor Calcium Release Channel,
pubmed-meshheading:20807279-Sarcoplasmic Reticulum,
pubmed-meshheading:20807279-Tachycardia, Ventricular,
pubmed-meshheading:20807279-Time Factors,
pubmed-meshheading:20807279-Verapamil
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
|
|
pubmed:affiliation |
Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
